ReviewInternational journal of clinical and experimental pathology2019
Association between dopamine receptor D2 TaqIA polymorphism and Parkinson disease risk: a meta-analysis.
Review in International journal of clinical and experimental pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Novel Pharmacotherapies in Parkinson's Disease.Neurotoxicity research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although many publications have evaluated the correlation between dopamine receptor D2 (DRD2) TaqIA polymorphism and Parkinson disease (PD), the results remain inconclusive. In order to further address the association between DRD2 TaqIA polymorphism and PD risk, we performed a meta-analysis of all eligible studies from more databases. Related studies were identified from six databases involving PubMed, Springer Link, Ovid, Chinese Wanfang Data Knowledge Service Platform, Chinese National Knowledge Infrastructure (CNKI), and Chinese Biology Medicine (CBM) through Octorber 2018. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess the strength of the associations. A total of 13 studies including 3558 PD patients and 10186 controls were involved in this meta-analysis. Overall, no significant association was found between DRD2 TaqIA polymorphism and PD risk in the total population. A further subgroup study by ethnicity showed a significant association between DRD2 TaqIA polymorphism and PD in Caucasians (for A1 vs. A2: P=0.02, OR=1.14, 95% CI: 1.02-1.27; for (A1A1 + A1A2) vs. A2A2: P=0.03, OR=1.16, 95% CI: 1.02-1.33). No significant results were observed in Asians. In conclusion, this meta-analysis provides evidence that DRD2 TaqIA polymorphism may contribute to the PD development in Caucasians, and large-scale well-designed studies are required in future to confirm this conclusion.
Indexed as
Identifiers
31934160PMC6949836What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.